Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.35 on Tuesday. The stock has a market cap of $1.95 million, a price-to-earnings ratio of -0.05 and a beta of 0.49. Oragenics has a 1 year low of $0.28 and a 1 year high of $7.74. The firm has a 50-day moving average of $0.41 and a two-hundred day moving average of $1.05.

Oragenics (NYSE:OGEN) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.